Results 151 to 160 of about 983 (198)

A Novel Liquid Chromatography‐Tandem Mass Spectrometry Method for Estimation of Solriamfetol: An Application to Spiked Human Plasma

Separation Science Plus
Solriamfetol, an emerging drug for the treatment of excessive daytime sleepiness along with narcolepsy and obstructive sleep apnoea. It acts as a dopamine and norepinephrine reuptake inhibitor. The present study aimed to develop a liquid chromatography‐
N. Prashant K., V. Lakshmi. A, Suvarna Yenduri   +2 more
semanticscholar   +1 more source

An Efficient Synthesis of Solriamfetol Hydrochloride Substantially Free From Impurities: Identification, Synthesis, and Characterization of Novel Impurities

ChemistrySelect
An improved, novel, and efficient three‐step synthetic process for the production of solriamfetol hydrochloride ( 1 ), an anti‐narcolepsy medication designed to address excessive daytime sleepiness, has been disclosed.
Dattatraya M. Chaudhari, Jaydeo T. Kilbile, Sanket P. Zanjad, Suchita S. Gadekar, Sarang V. Babar, K. Jawale, Suryakant B. Sapkal   +6 more
semanticscholar   +1 more source

Solriamfetol and m-chlorophenylpiperazine cause false positive amphetamine results on urine drug screening

Journal of Analytical Toxicology, 2023
Abstract Urine drug screening by immunoassay is a common method to quickly identify drug exposures in the emergency setting and to detect unexpected drug exposures in a variety of patient care and occupational health settings. Although they provide rapid results, immunoassays are susceptible to cross-reactivity with other medications and
Ashley R Rackow, Claire E Knezevic
openaire   +2 more sources

Solriamfetol: adverse event profile examined based on FAERS data

Reactions Weekly
openaire   +2 more sources

Solriamfetol in excessive daytime sleepiness: a profile of its use

Drugs & Therapy Perspectives, 2020
Oral solriamfetol (Sunosi™), a selective dopamine and norepinephrine reuptake inhibitor, is approved to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA) in the USA and EU.
Emma D. Deeks, Young-A Heo
openaire   +1 more source

Solriamfetol improves driving performance in patients with excessive sleepiness

The Brown University Psychopharmacology Update, 2022
Adults with excessive daytime sleepiness associated with obstructive sleep apnea (OSA) who received solriamfetol showed improved driving performance relative to placebo in a two‐period crossover study. Solriamfetol resulted in reduced standard deviation of lateral position (SDLP) at 2 and 6 hours post‐dose.
openaire   +1 more source

Results of the SHARP Study: A Randomized, Placebo-Controlled, Double-Blind, Repeated-Measures, Crossover, Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in Obstructive Sleep Apnea With Excessive Daytime Sleepiness and Cognitive Impairment.

Chest
BACKGROUND Obstructive sleep apnea (OSA) causes episodes of fragmented sleep and intermittent hypoxia and leads to excessive daytime sleepiness (EDS). Deficits in cognitive function are a troublesome symptom in patients with OSA and EDS.
H. Van Dongen, E. Leary, C. Drake, Richard K. Bogan, Judith Jaeger, Russell Rosenberg, C. Streicher, H. Tabuteau   +7 more
semanticscholar   +1 more source

1007 Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition

Sleep
Cognitive impairment is a burdensome symptom in many patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).
Hans Van Dongen, E. Leary, Graham M L Eglit, C. Drake, Richard Bogan, Judith Jaeger   +5 more
semanticscholar   +1 more source

1215 Adjunctive Use of Solriamfetol in Pediatric Excessive Daytime Sleepiness: A Single Center Experience

Sleep
Solriamfetol (Sunosi) has been FDA-approved for adults aged 18 years or older particularly for excessive daytime sleepiness (EDS) associated with obstructive sleep apnea or narcolepsy.
Robin T. Varughese, Christine Palladino, Sanjeev Kothare   +2 more
semanticscholar   +1 more source

Solriamfetol titration and administration (start): Dosing and titration strategies in patients with narcolepsy starting solriamfetol

Journal of the Neurological Sciences, 2021
Michael Thorpy, Danielle Hyman, Gregory Parks, Abby Chen, Catherine Foley, Diane Ito, Haramandeep Singh   +6 more
openaire   +1 more source